Download Image
    
Share
  
Post
Amiodarone for COVID-19
1 study with 143 patients
Hospital Icon Control
Hospital Icon Amiodarone Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Amiodarone studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -103% Mortality -103% RCTs -103% Late -103% Favorsamiodarone Favorscontrol
Jan 23
2023
 Money et al., Cureus, doi:10.7759/cureus.34109 Amiodarone for the Treatment of Arrhythmias in COVID-19 Patients Does Not Increase the Risk of Pulmonary Fibrosis: A Retrospective Cohort Study
Retrospective 420 COVID-19 patients (210 with amiodarone exposure, 210 without) showing no significant difference in pulmonary fibrosis risk with amiodarone use.
Sep 30
2022
 Navarese et al., Cardiology Journal, doi:10.5603/CJ.a2022.0072 Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial
103% higher mortality (p=0.33), 52% higher ventilation (p=0.43), and 30% worse recovery (p=0.19). RCT 215 hospitalized non-intensive care COVID-19 patients showing no significant difference in clinical improvement with amiodarone or verapamil. The trial, which aimed to assess the effects of ion channel inhibitors on COVID-19 progressi..